Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share By
Car-Nk Cells for Haematological Cancers Publisher



Noorafrooz M1 ; Gale RP2 ; Noorafrooz R1 ; Ghods S1
Authors

Source: Best Practice and Research: Clinical Haematology Published:2025


Abstract

Chimeric antigen receptor-natural-killer (CAR-NK)-cells are a promising cancer cell therapy. Several features of CAR-NK-cells are suggesting an advantage over CAR-T-cells such as less complex manufacturing, “off-the-shelf” use and lower risks of cytokine release (CRS) and immune effector cell-associated neurotoxicity syndromes (ICANS). CAR-NK-cells derived from several sources are associated with promising pre-clinical and clinical results in haematological cancers. We comprehensively discuss the current landscape of CAR-NK-cell therapy in haematological cancers emphasizing recent progress and future directions. Additionally, we explore the biological mechanisms, engineering and sources of CAR-NK-cells. CAR-NK-cell therapy offers a safe, accessible and efficient option for haematological cancers. © 2025 Elsevier Ltd
Other Related Docs
5. Car-Nk Cells: A Promising Cellular Immunotherapy in Lymphoma, Expert Opinion on Biological Therapy (2023)